An accurate determination of human epidermal growth factor receptor 2 (Her2) status in women with breast cancer is mandatory to identify patients who will benefit from trastuzumab-based therapy.

Pennacchia, I., Vecchio, F. M., Carbone, A., Arena, V., HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?, <<APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY>>, 2015; 23 (1): 31-35. [doi:10.1097/PAI.0000000000000047] [http://hdl.handle.net/10807/70983]

HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?

Pennacchia, Ilaria;Vecchio, Fabio Maria;Carbone, Arnaldo;Arena, Vincenzo
2015

Abstract

An accurate determination of human epidermal growth factor receptor 2 (Her2) status in women with breast cancer is mandatory to identify patients who will benefit from trastuzumab-based therapy.
Inglese
Pennacchia, I., Vecchio, F. M., Carbone, A., Arena, V., HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?, <>, 2015; 23 (1): 31-35. [doi:10.1097/PAI.0000000000000047] [http://hdl.handle.net/10807/70983]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/70983
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact